INVESTIGATIVE REPORTS

Morphological Assessment of the Effects of Cyclosporin A on Mast Cell - Nerve Relationship in Atopic Dermatitis

MASAHIKO TOYODA and MASAHIKO MOROHASHI

Department of Dermatology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Toyama, Japan

There is considerable clinical and experimental evidence that cyclosporin A has powerful therapeutic effects on severe, therapy-resistant atopic dermatitis. To further clarify the mechanism of beneficial action of cyclosporin A for atopic dermatitis, we assessed its effects on mast cell morphology and on the topographical relationship between mast cells and cutaneous nerves in lesional skin of atopic dermatitis. The ultrastructural features of mast cell - specific granules in cyclosporin A-treated skin compared with those in the pretreated skin included an increase in the stable granule population and the disappearance of signs of granule exocytosis. The close apposition of mast cells to peripheral nerve fibres in the upper dermis and an invasion of mast cells into nerve bundles in the lower dermis were immunohistochromically noted, and an intimate association between mast cells and unmyelinated dermal nerves or Schwann cells was observed ultrastructurally in the pretreated lesional skin. After cyclosporin A therapy, the close interrelation of mast cells and cutaneous nerves was not seen. These findings suggest that cyclosporin A may exert its therapeutic efficacy by inhibiting mast cell activation, and by affecting the interaction between mast cells and nerves, which may explain the beneficial therapeutic action of cyclosporin A in the management of the disease. Key words: electron microscopy; immunohistochemistry; skin; therapy.

(Accepted February 27, 1998.)


M. Toyoda, Department of Dermatology, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930-0194, Japan.

The pathogenesis of atopic dermatitis (AD) is multifactorial and involves genetic, physiological, pharmacological, psychological, and immunologic factors. Mast cells (MCs) are known to participate not only in immediate-type hypersensitivity but also in chronic inflammation and delayed immune response, and to contribute to the pathomechanism of various allergic skin disorders, such as AD (1, 2). The nervous system is also closely associated with exacerbation as well as onset of AD through emotional stress (3), altered patterns of cutaneous innervation, and abnormal expression of neuropeptides in lesional skin (4–7). All of these factors could contribute to interaction between the nervous system and the immune system, referred to as neurogenic inflammation in AD. Histamine released from MCs is thought to amplify neurogenic inflammation in the skin, and, in turn, some types of neuropeptides released from sensory nerve endings upon stimulation are capable of inducing the release of chemical mediators from skin MCs, which leads to a cell-mediated inflammatory skin condition (1, 8). In addition, an intimate spatial relationship of MCs to peripheral nerve fibres has been reported in lesional skin of AD patients (9), and therefore close interaction between MCs and the cutaneous nervous system may play a significant role in the pathophysiology of AD.

Cyclosporin A (CsA) has been shown to be a potent and effective therapeutic agent in many inflammatory and immunologically mediated dermatologic disorders, including AD. Many clinical trials have confirmed the remarkable efficacy of oral CsA therapy in patients with severe, drug-resistant AD, which results in a marked reduction in disease severity as well as in itch intensity (10–12). Although the exact mechanism of the beneficial effects of CsA therapy in AD has not been sufficiently elucidated because of its manifold modes of action, most of the evidence suggests that CsA suppresses T-lymphocyte function and the production of cytokines involved in the immunopathogenesis of AD (13, 14). Although there have been several studies about the effects of CsA on MCs (1, 15–18), a morphological assessment of human skin MCs and the MC - nerve relationship in lesional skin of AD patients treated with CsA has never been reported in the literature.

The aim of this study was to ascertain whether CsA therapy elicits alterations in the morphology of MCs and/or in the topographical relationship between MCs and cutaneous nerves in patients with severe, chronic AD.

MATERIALS AND METHODS

Patients

Informed consent was obtained from two male patients, aged 25 and 28, with severe, constitutional eczematous lesions and with a chronic course of more than 10 years who fulfilled the diagnostic clinical criteria for AD (19, 20). They were treated with CsA (Sandimmune, Novartis Pharma K.K.), at a dose of 5 mg/kg/day, given orally for 1 month as a single evening dose (21). Both patients had been resistant to various other systemic and topical treatments in the past. Systemic treatments for AD, such as PUVA therapy and oral administration of antihistamines, had been discontinued 4 weeks before the start of treatment with CsA, and neither patients had received any topical therapy for 2 weeks before treatment. No other concurrent therapy was given during the course of CsA therapy in either patient.

Biopsies and tissue processing

Four-millimeter punch biopsy specimens were obtained from lichenified lesions on the back of each patient before treatment with CsA. Subsequently, biopsy specimens were taken 1 month after the start of CsA therapy from lesional skin near sites from which the pretreatment specimens had been obtained.

Half of each biopsy specimen was fixed in 10% buffered neutral formalin and embedded in paraffin. For histological examination, 4 μm tissue sections were stained with hematoxylin and eosin and with 1% toluidine blue, pH 7.0, to identify MCs. For immunohistochemical studies, the formalin-fixed and paraffin-embedded tissue sections were deparaffinized, rehydrated, rinsed in phosphate-buffered saline, and
then stained using the avidin-biotin-peroxidase complex method (22) with
an antibody recognizing the general neuronal marker, protein gene pro-
duct 9.5 (Ultracrome Ltd., Isle of Wight, UK), which stains various popu-
lations of cutaneous nerves (23). Controls examined consisted of sections
in which the primary antibody was omitted and/or was substituted by an
irrelevant monoclonal antibody of a similar isotype. After the immunohis-
tochemical procedures, the sections were counterstained with toluidine
blue, which made it possible to recognize the topographical relationship
between MCs and nerves using conventional microscopy.

The remaining halves of the biopsy specimens for electron micro-
scopy were fixed in 2.5% glutaraldehyde and postfixed in 2% osmium
tetroxide, and then stained en bloc in 3% aqueous uranyl acetate. They
were dehydrated in graded steps of ethanol and embedded in Epon 812.
Ultrathin sections (70 nm) were doubly stained in uranyl acetate and
lead citrate prior to examination in an H-300 transmission electron micro-
scope (Hitachi, Tokyo) at an acceleration voltage of 100 kv.

Quantification of MCs
The number of MCs in the papillary dermis and the subpapillary region
was counted in 10 non-serial sections for each skin sample in 10 differ-
ent visual fields at a magnification of × 400 with a light microscope,
and mean number of MCs was recorded for each skin sample. The
results of MC number before and after treatment with CsA were ana-
lysed statistically using a paired t-test.

RESULTS
A substantial clinical improvement, characterized by a rapid
relief of itch intensity and a remarkable reduction in disease
severity, was achieved after oral administration of CsA in both
patients. The histological changes observed in skin sections
before and after CsA treatment paralleled the clinical improve-
ment. After the CsA therapy, a clear reduction in the dermal
mononuclear cell infiltrate was observed, as was a remarkable
decrease in epidermal thickness and in the number of intraepi-
dermal microvesicles.

The number of MCs
In lesional skin before treatment, the number of MCs was
73.4 ± 6.2 (mean ± SD) and 80.5 ± 8.1 in the 2 patients in 10
visual fields at a magnification of × 400. After 1 month of
CsA treatment, a slight but statistically insignificant reduction
was observed in MC number of the 2 patients (68.5 ± 5.5 and
75.0 ± 4.9, respectively). Morphological changes of MCs, such as
in their cell size or in their distribution, were not observed at
the light microscopic level before or after CsA therapy.

Ultrastructure of MCs
A comparison of specimens taken before and after treatment
with CsA showed some interesting ultrastructural alterations
in MCs, especially in their specific granules. In lesional skin
prior to treatment, MCs possessed specific granules which
exhibited various degrees of degranulation. Most of the specific
granules were homogeneous, showing decreased electron den-
sity of the granule matrix, whereas adjacent homogeneous
granules were often fused with each other, forming masses of
floculent material. MC granules were frequently in contact
with extracellular spaces, a sign of granule exocytosis (Fig. 1a).
MC granules were also observed in extracellular spaces near MCs in some sections. By comparison, MCs in the skin of AD patients after 1 month of CsA therapy pos-
sessed not only homogeneous granules but also a population
of stable granules which were uniformly electron-dense and
surrounded by the distinct outline of a perigranular membrane.
Exocytosis of MC granules, as was seen in MCs in skin before
treatment with CsA, were rarely observed (Fig. 1b).

The relationship between MCs and nerve fibres
Immunoreactivity for protein gene product 9.5 in lesional skin
of AD patients was seen in the epidermis, dermis and around
vessels and cutaneous adnexa. In sections of skin taken prior to
CsA therapy, counterstaining with toluidine-blue following
immunostaining with protein gene product 9.5 showed the
close apposition of MCs to peripheral nerve fibres mainly in
the perivascular area of the upper dermis (Fig. 2a). Nerve fibres
were often surrounded by several MCs (Fig. 2b). In the lower
dermis, many trespassing nerve bundles were also immuno-
reactive for protein gene product 9.5. Lesional skin taken
before CsA treatment showed invasion or attachment of MCs
to those nerve bundles (Fig. 2c, d). In contrast, such close asso-
ciation between MCs and cutaneous dermal nerve fibres seen in
untreated lesional skin was not observed in the skin of AD
patients after CsA treatment.

The intimate topographical relation between MCs and nerve
fibres in untreated lesional skin was amply confirmed by ultra-
structural studies. MCs showing degranulation processes were
in close or direct proximity to nerve bundles (Fig. 3a, b), and
some MCs showed close apposition to Schwann cells (Fig. 3c).
These findings were never observed in any sections of lesional skin
from CsA-treated AD patients.
DISCUSSION

It has been recognized for some time that the beneficial effects of CsA in the treatment of patients with AD can be attributed primarily to inhibition of T-helper cell activation, which results in the suppression of cytokine production, such as IL-2, IL-4 and IL-5 (14). CsA also indirectly inhibits the growth and differentiation of B lymphocytes and the functional activities of mononuclear phagocytes, Langerhans’ cells and eosinophils (1). Furthermore, our recent immunohistochemical study revealed that CsA may play a therapeutic role via effects on the cutaneous nervous system through altered innervation and neuropeptide expression in lesional skin of AD (24). In addition to these previously reported modes of CsA action, the present morphological study offers a strong indication that CsA may exert its clinical efficacy for AD by inhibiting MC activation and by alterations of a topographical relationship between MCs and cutaneous nerves in lesional skin, suggesting a new aspect of the effects of CsA in the management of the disease.

In allergic diseases, exposure of sensitized subjects to specific allergens causes the activation of tissue MCs, and a subsequent immediate-type hypersensitivity response and, in some individuals, a late phase response, which may also be involved in the pathogenesis of AD (25). It is known that there is enhanced histamine release by cutaneous MCs specifically upon immunologic challenge of AD patients compared with healthy controls (26). MCs containing the proteinases trypsin and chymase in their secretory granules are the predominant MC type in normal human skin, but MCs containing only trypsin have been reported to be significantly increased in lesional AD skin (27). Morphologically, cutaneous MCs in lichenified lesions of AD patients show a significant increase in number accompanied by accelerated degranulation (28, 29), and a unique cluster formation by activated MCs, a feature characteristic of obstinate cases of AD (30). MCs are thus undoubtedly involved in the pathophysiology of AD.

We have demonstrated in this study that the number of MCs in lesional AD skin remained unchanged before and after 1 month of oral CsA administration, in spite of apparent clinical and histological improvement. This result seems to disagree with a previous report that numbers of mucosal MC were diminished in CsA-treated animals exhibiting graft-vs-host disease or helminth infections (31). This apparent discrepancy may result from several different factors in these studies, including types of diseases, the species and organs examined, the total dose of CsA administered and the duration of therapy. However, it is difficult to draw a conclusion at this time regarding the effect of CsA on the MC population in AD skin because of the low number of biopsies studied. The presence of MCs in lesional AD skin after CsA treatment may partially
the stable granule population, a decrease in homogeneous granules indicating an initial stage of degranulation, and the disappearance of adjacent granule fusion and subsequent exocytosis of granules after CsA treatment provide the first ultrastructural evidence of the effects of CsA on the inhibition of MC activation processes in AD skin. These findings support previous in vitro studies on the inhibitory effect of CsA on the immunologic activation of MCs (1, 15). Stellato et al. (15) reported that CsA rapidly and irreversibly inhibits the release of preformed (histamine) and of de novo synthesized (prostaglandin D2) mediators from purified human skin MCs challenged with anti-IgE. It is interesting to note that, in that study, CsA exerted no inhibitory effect on substance P-induced histamine release from MCs, suggesting that the inhibitory effect of CsA has a high degree of selectivity depending on the nature of the stimulus. In addition, MCs are able to produce a variety of cytokines, such as IL-4, IL-5, IL-6, tumour necrosis factor-α and interferon-γ, which are extensively involved in modulating inflammatory responses in the skin (1). TNF-α is an especially important determinant of inflammatory cell – endothelial cell adhesive interactions during the genesis of cellular inflammation in the skin (34), and within MC granules TNF-α is rapidly released into the extracellular space upon degranulation. Wershil et al. (16) reported that CsA interferes with the pathogenesis of IgE-, MC- and cytokine-dependent inflammatory reactions by inhibiting IgE-dependent TNF-α mRNA production and thus the synthesis of TNF-α protein. Taken together, the possibility that CsA may ameliorate disturbances of cell-mediated immunity in AD by suppressing the release of histamine, lipid mediators, active proteases and cytokines from MCs should be considered. Our ultrastructural findings in this study support the inhibitory effects of MC activation by CsA.

To our knowledge, this is the first study in which alterations of MC - nerve relationships following CsA therapy of AD lesional skin have been observed using immunohistochemical and ultrastructural methods. The close interaction between MCs and cutaneous nerves has long been recognized. Electrical stimulation of nerve fibres or various neuropeptides antidromically released from peripheral nerve fibres induces MC degranulation (8, 35). Although the close topographical relationship of cutaneous nerve fibres or the anatomical direct contact of neuropeptide-containing sensory nerves with MCs has already been described (36, 37), the exact role of this interaction remains to be elucidated. Sugiu et al. (9) observed MC invasion into peripheral nerves in 9 of 10 AD lesional skin specimens at the ultrastructural level. They proposed that the invasion of MCs showing degranulation into dermal nerves may be related to provoking or aggravating the itch in AD. Our immunohistochemical observation revealed the close apposition of MCs to peripheral nerve fibres mainly in the perivascular area of the upper dermis. Taking into account the decrease in density of perivascular nerve fibres in CsA-treated AD skin compared with AD skin prior to treatment (24), lack of this apposition between MCs and perivascular nerves after CsA therapy may be due to the effect of CsA on the innervation in lesional AD skin. In addition, the invasion of MCs into trespassing nerve bundles was observed in the lower dermis of AD lesional skin. The close association between MCs and unmyelinated dermal nerves or Schwann cells was further confirmed by electron microscopy. These findings support the concept that interactions between MCs and the cutaneous nervous system may play an important role in the pathogenesis of AD.

explain the relapses noted in several clinical trials (12, 19, 32, 33) following cessation of CsA administration.

We observed visible ultrastructural alterations of MC-specific granules in CsA-treated AD skin compared with AD skin prior to treatment. Our observations of an increase in

**Acta Derm Venereol (Stockh) 78**
However, this intimate interrelation of MCs to nerves was not recognized at all in either AD case examined after 1 month of CsA therapy.

The possibility that the changes seen in this study are not directly due to CsA but simply a non-specific effect of resolution of AD cannot be excluded at present. Effects which are specific to CsA and not a non-specific effect of lesional clearance could be demonstrated by studying biopsies taken a short time after starting CsA, although biopsies were taken after a month of CsA treatment in our study. A comparison with the findings in the patients treated with other methods, such as topical steroids, has also to be performed. Nevertheless, our results suggest that CsA may have more potential modes of action for the management of AD than hitherto suspected, and we believe that this study should be one step in clarifying the significance of the MC - nerve relationship in AD and the mechanism of possible effects on these interactions by CsA.

REFERENCES


